Continuous Manufacturing Systems Market Size Expected to Reach USD 2148.06 Mn at 12.04% CAGR by 2034

By GlobeNewswire On Apr 28, 2026

The global continuous manufacturing systems market size was valued at USD 772.13 million in 2025 and is predicted to hit around USD 2148.06 million by 2034, rising at a 12.04% CAGR, a study published by Towards Healthcare Research & Consulting, a sister firm of Precedence Research.

Ottawa, April 28, 2026 (GLOBE NEWSWIRE) — The global continuous manufacturing systems market size is calculated at USD 865.09 million in 2026 and is expected to reach around USD 2148.06 million by 2034, growing at a CAGR of 12.04% for the forecasted period.

The Complete Study is Now Available for Immediate Access | Download the Free Sample Pages of this Report @ https://www.towardshealthcare.com/download-sample/5791

With advancements in manufacturing technology innovations, a rapid shift towards continuous manufacturing was observed, driven by its potential in real-time monitoring, enhanced quality control, and improved scalability. The primary applications of continuous manufacturing lie in the production of RNA-based therapeutics, including self-amplifying RNA (saRNA), messenger RNA (mRNA), and circular RNA. The continuous manufacturing platforms are promising solutions to maintain rigorous quality standards and increase production efficiency. Continuous manufacturing enables the integration of all unit operations into a continuous and seamless process, while reducing production timelines.

The Continuous Manufacturing Systems Market: Highlights

The global continuous manufacturing systems market to cross USD 689.15 million in 2024.
Market projected at USD 2148.06 million by 2034.
CAGR of 12.04% expected in between 2025 to 2034.
North America dominated the continuous manufacturing systems market share in 2024.
Asia-Pacific is expected to grow at the highest CAGR in the market during the forecast period.
By type of molecules, the small molecules segment held the largest revenue market share in 2025.
By type of molecules, the biologic segment is expected to grow at the fastest CAGR in the market during the studied years.
By type of equipment, the continuous bioreactor segment dominated the market in 2025.
By type of equipment, the granulators segment is expected to grow at the fastest CAGR in the market during the studied years.
By scale of operation, the preclinical segment led the market in 2025.
By scale of operation, the clinical segment is expected to grow at the fastest CAGR in the market during the studied years.

You can place an order or ask any questions, please feel free to contact us at [email protected]

Market Overview

Innovative and Progressive Alternatives to Biopharma Manufacturing

The continuous manufacturing systems market revolves around novel approaches to conventional fed-batch processes, which play a pivotal role in the production of complex biologics. This innovation reduces the need for batch-to-batch transfers, streamlines the entire production chain, and minimizes downtime. Continuous manufacturing helps to achieve enhanced efficiency and productivity, enhanced product quality, reduced emissions, flexible design, and cost-effective manufacturing. The companies are dedicated to establishing an efficient and reliable continuous bioprocessing workflow.

Unique Challenges in Continuous Manufacturing

The innovative technologies, including continuous manufacturing, impose certain challenges that are associated with the integration of upstream and downstream processes. These technologies impose operational and logistical challenges, bring bioburden control, and enable risk management. For instance, the implementation of the perfusion filtration devices in the process flow leads to greater protein retention inside the bioreactor and results in reduced protein yield. Moreover, the operational hurdles are brought by the clogging of filtration devices, which disrupts production. They need timely interventions to maintain product quality and process efficiency.

Solutions to Overcome Challenges through Innovation

Advancements in continuous manufacturing revolutionized the production of costly biologics. This novel technology proves to be promising to enhance product accessibility and boost productivity and efficiency in the manufacturing of biologics. A continuous manufacturing technology utilizes compact equipment and addresses the primary challenges in the production of biologics. The manufacturers need to pay close attention to maintain sterility and prevent bioburden buildup, which is important to ensure the quality and safety of products. They also identify and mitigate risks associated with continuous manufacturing, such as equipment failures and process interruptions, which is essential to ensure uninterrupted production.

Potential of Continuous Manufacturing in Biopharma Innovations

Continuous manufacturing is a highly efficient approach in manufacturing that offers several benefits to businesses. The businesses improve product quality, increase productivity, and reduce costs by optimizing the production processes. They also make efforts to resolve challenges associated with the complexity of the process, high initial investment, the risk of equipment failure, and maintenance.

Become a valued research partner with us – https://www.towardshealthcare.com/schedule-meeting

The Continuous Manufacturing Systems Market: Regional Analysis

North America dominated the market in 2025, owing to supportive government policy and incentives for R&D, adoption of smart manufacturing tools, advancements in process analytical control, and supply chain resilience. The top market players, such as Merck, have launched a $1 billion vaccine manufacturing plant in North Carolina. Merck has integrated cutting-edge technologies like 3D printing and AI to enable more flexible and faster vaccine production. The companies have invested in digital supply chain models to improve current networks.

U.S. Market Analysis

The continuous manufacturing systems market in the U.S. experiences a momentous growth due to the U.S. FDA initiatives, streamlined approvals for domestic drug plants, and regulatory harmonization. The U.S. and Canada are dedicated to localized biopharma manufacturing and innovation in production technologies. The leading firms have launched state-of-the-art facilities through government incentives to strengthen the domestic supply chain.

Asia Pacific is expected to grow at the fastest rate in the market during the forecast period due to industrial shift towards cost-efficient and automated production, government-led digital initiatives, and rapid industrialization. Asia Pacific has emerged as a rapid biopharma manufacturing powerhouse due to the notable rise of biopharma expansion projects in countries like India and Singapore. Companies like Bharat Biotech, Merck & Co., Samsung Biologics, AstraZeneca, Lonza, and AGC Biologics are expanding manufacturing capacity to meet global demand.

India Market Analysis

The continuous manufacturing systems market in India is advancing due to the establishment of reliable and advanced production bases to avoid supply chain disruptions, and the adoption of advanced manufacturing and technology solutions. The government of India provides many schemes to support domestic innovation and reduce dependency on pharmaceutical imports.

For instance,

In February 2026, DFE Pharma launched a continuous manufacturing platform to boost the development of formulations in Hyderabad. This new platform is well-equipped with cutting-edge equipment and expertise in collaboration with Gericke.

Get the latest insights on life science industry segmentation with our Annual Membership: https://www.towardshealthcare.com/get-an-annual-membership

The Continuous Manufacturing Systems Market: Segmentation Analysis

Type of Molecules Insights

The small molecules segment dominated the continuous manufacturing systems market in 2025, owing to high-level process integration, the ability of continuous manufacturing systems to handle hazardous reactions, and improved sustainability. The leading companies like Pfizer Inc., Eli Lily, Amgen Inc., and GSK are involved in the design and implementation of their small molecule drug substance processes. The adoption of continuous manufacturing results in shorter supply chains, supply chain security, improved product quality, and cost benefits.

The biologic segment is expected to grow at the fastest rate in the continuous manufacturing systems market during the forecast period due to the increasing partnerships of biologics developers with contract development and manufacturing organizations (CDMOs) to address affordability and accessibility. These partnerships give drug developers access to innovative solutions for the production of biologics. The upstream and downstream processes are performed in continuous biologics manufacturing to produce a drug substance.

Type of Equipment Insights

The continuous bioreactor segment led the continuous manufacturing systems market in 2025, owing to the integral functions of these bioreactors to ensure a consistent output of product. They simplify downstream purification and improve overall batch consistency. They are critical for delicate proteins such as coagulation factors and enzymes, and they protect labile products.

The granulators segment is expected to grow rapidly in the continuous manufacturing systems market during the studied period due to their potential benefits, such as improved flowability, improved compressibility, uniform drug distribution, reduced dust, and controlled release. The five common types of pharmaceutical granulators are oscillating granulators, roller compactor granulators, high shear granulators, vibrating granulators, and fluid bed granulators. They are generally chosen based on production needs, operational factors, and material properties.

Scale of Operation Insights

The preclinical segment dominated the continuous manufacturing systems market in 2025, owing to the core roles of preclinical scale of operations, including process development and optimization, and early implementation of process analytical technology. The manufacturers use the preclinical scale to develop the drug delivery system and test for stability. The risk mitigation and validation stage enables early process validation to ensure a consistent production.

The clinical segment is expected to grow at a rapid rate in the continuous manufacturing systems market in the upcoming period due to accelerated drug development, material efficiency, and simplified scale-up. The regulatory bodies, like the U.S. FDA and EMA, contribute to the adoption of continuous manufacturing at the clinical scale. The clinical scale ensures consistent quality in the produced drug for 100 clinical participants, which is identical to the drug produced for 1 million commercial patients.

Access our comprehensive healthcare dashboard for detailed market insights, segment breakdowns, regional performance, and company profiles: https://www.towardshealthcare.com/access-dashboard

The Continuous Manufacturing Systems Market Companies

Coperion GmbH
Glatt GmbH
Korsch AG
Munson Machinery Co., Inc.
GEA Group AG
Thermo Fisher Scientific Inc.
Hosokawa Micron Corporation
Scott Equipment Company
Sturtevant, Inc.
L.B. Bohle Maschinen Verfahern GmbH

Browse More Insights of Towards Healthcare:

The global laboratory information management systems market size is calculated at US$ 2.65 billion in 2025, grew to US$ 2.82 billion in 2026, and is projected to reach around US$ 4.98 billion by 2035. The market is expanding at a CAGR of 6.52% between 2026 and 2035.

The global healthcare digital authentication market size was estimated at USD 5.04 billion in 2025 and is predicted to increase from USD 5.8 billion in 2026 to approximately USD 20.46 billion by 2035, expanding at a CAGR of 15.04% from 2026 to 2035.

The global mental health EHR software market size was estimated at USD 1.77 billion in 2025 and is predicted to increase from USD 2.04 billion in 2026 to approximately USD 7.16 billion by 2035, expanding at a CAGR of 15% from 2026 to 2035.

The global mental health software market size was estimated at USD 6.06 billion in 2025 and is predicted to increase from USD 6.77 billion in 2026 to approximately USD 18.38 billion by 2035, expanding at a CAGR of 11.74%% from 2026 to 2035.

The global mental health practice management software market size was estimated at USD 2.42 billion in 2025 and is predicted to increase from USD 2.72 billion in 2026 to approximately USD 7.81 billion by 2035, expanding at a CAGR of 12.44% from 2026 to 2035.

The global AI in mental health chatbots market size was estimated at USD 59.49 billion in 2025 and is predicted to increase from USD 64.06 billion in 2026 to approximately USD 124.79 billion by 2035, expanding at a CAGR of 7.69% from 2026 to 2035.

The global mental health platform market size is expected to be worth around USD 37.26 Billion by 2035, from USD 7.15 billion in 2025, growing at a CAGR of 17.95% during the forecast period from 2026 to 2035.

The global mental health technology market size was estimated at USD 10.08 billion in 2025 and is predicted to increase from USD 11.97 billion in 2026 to approximately USD 56.17 billion by 2035, expanding at a CAGR of 18.74% from 2026 to 2035.

The U.S. digital mental health market size was estimated at USD 7.46 billion in 2025 and is predicted to increase from USD 8.97 billion in 2026 to approximately USD 47.13 billion by 2035, expanding at a CAGR of 20.25% from 2026 to 2035.

The global AI voice agents in healthcare market size was estimated at USD 472 million in 2025 and is predicted to increase from USD 650.65 million in 2026 to approximately USD 11,695.26 million by 2035, expanding at a CAGR of 37.85% from 2026 to 2035.

Segments Covered in the Report

By type of molecule

Small molecule
Biologic

By type of equipment

Mixers
Granulators
Continuous bioreactor
Reactors and others

By scale of operation

Preclinical
Clinical
Commercial

By Region

North America
- U.S.
- Canada
Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
Asia Pacific
- Japan
- China
- India
- South Korea
- Australia
- Thailand
Latin America
- Brazil
- Mexico
- Argentina
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait

Immediate Delivery Available | Buy This Research Report Now @ https://www.towardshealthcare.com/checkout/5791

Access our exclusive, data-rich dashboard dedicated to the healthcare market – built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway.

Access our comprehensive healthcare dashboard for detailed market insights, segment breakdowns, regional performance, and company profiles: https://www.towardshealthcare.com/access-dashboard

Access the Dashboard: https://www.towardshealthcare.com/access-dashboard

About Us

Towards Healthcare Research & Consultingis a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research. Dedicated to advancing innovation in the life sciences sector, we build strategic partnerships that generate actionable insights and transformative breakthroughs. As a global strategy consulting firm, we empower life science leaders to gain a competitive edge, drive research excellence, and accelerate sustainable growth.

You can place an order or ask any questions, please feel free to contact us at [email protected]

Europe Region: +44 778 256 0738

North America Region: +1 8044 4193 44

APAC Region: +91 9356 9282 04

Web: https://www.towardshealthcare.com

Our Trusted Data Partners

Find us on social platforms: LinkedIn | Twitter | Instagram | Medium | Pinterest

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. NewIndiaObserver.com takes no editorial responsibility for the same.